7/16/2013

Cognoptix has created a noninvasive eye-scanning device, called SAPPHIRE II, that uses a specific beta amyloid signature in the eye to determine whether a patient is at risk for Alzheimer's disease. The Acton, Mass.-based company will release information on the device Wednesday at a conference in Boston.

Related Summaries